Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding

First Potential Targets Are Spinocerebellar Ataxia And Huntington's Disease

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.